The genomic simplicity of differentiated cancers derived from thyroid follicular cells offers
unique insights into how oncogenic drivers impact tumour phenotype. Essentially, the main …

The identification of mutationally activated BRAF in many cancers altered our conception of
the part played by the RAF family of protein kinases in oncogenesis. In this Review, we …

Purpose We report the efficacy and safety of dabrafenib (BRAF inhibitor) and trametinib
(MEK inhibitor) combination therapy in BRAF V600E–mutated anaplastic thyroid cancer, a …

Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we
describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic …

Thyroid cancer is a common endocrine malignancy. There has been exciting progress in
understanding its molecular pathogenesis in recent years, as best exemplified by the …

The identification of driver oncogenes has provided important targets for drugs that can
change the landscape of cancer therapies. One such example is the BRAF oncogene, which …

MAPK signaling inhibitor (MAPKi) therapies show limited efficacy for advanced thyroid
cancers despite constitutive activation of the signaling correlates with disease recurrence …

Advanced human thyroid cancers, particularly those that are refractory to treatment with
radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene …

Differentiated thyroid cancers are more frequent in women than in men. These different
frequencies may depend on differences in patient's behavior and in thyroid investigations …

Tumours can arise from thyroid follicular cells if they acquire driver mutations that
constitutively activate the MAPK signalling pathway. In addition, a limited set of additional …